This growth is driven by the increasing prevalence of type 2 diabetes and the broad availability of GLP-1 receptor agonists for its treatment
Most patients tolerate this without symptoms, but those with underlying arrhythmias or cardiovascular disease should be monitored
In the U.S., approximately 38.4 million people, or 11.6% of the population , have diabetes, with millions more pre-diabetic or overweight, creating a large pool of potential GLP-1 users
Its Weight Management Protocols offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral run through licensed clinical oversight, and pairing them with genetic context turns a prescription into an informed conversation with your provider rather than a blind start
Protect your muscle Prioritize your protein Move your body Advocate for your health You are worth this level of care
Availability subject to change